Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 11/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420176 | 0.79 | RBP4 (0.42) | CCR4L3MBTL3L3MBTL1KDM4ENPY2R | |
| SCHEMBL12552663 | 0.74 | MAPK1 (0.43) | L3MBTL3L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL12580747 | 0.70 | HPGD (0.51) | CCR4L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL1420086 | 0.69 | NPY2R (0.47) | ALDH1A1NPY2RHRH3HPGD | |
| SCHEMBL4257753 | 0.68 | L3MBTL1 (0.50) | CCR4L3MBTL3L3MBTL1MBTD1ALDH1A1 | |
| SCHEMBL1420168 | 0.68 | KHK (0.40) | L3MBTL3L3MBTL1MBTD1KDM4EALDH1A1 | |
| SCHEMBL10203175 | 0.67 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL12552673 | 0.67 | RBP4 (0.48) | KDM4EALDH1A1HPGD | |
| SCHEMBL1420172 | 0.65 | KDM4E (0.49) | L3MBTL3L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL12548172 | 0.65 | GBA1 (0.46) | L3MBTL1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | G6PD, DHFR, SGMS1 | CCR4 1601/4885L3MBTL3 3831/4885L3MBTL1 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.